Publications by authors named "Adam D Cohen"

Claim this Profile
O
Outcomes of Radiation Integrated with T-cell-engaging Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma.
Heta Patel, Harper Hubbeling, Kyle L Yu, Maribel Carpenter, Michael J LaRiviere, Adam D Cohen

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes of relapse after teclistamab therapy in multiple myeloma.
Kyle L Yu, Matthew Ho, Luca Paruzzo, Federico Stella, Heta Patel, Adam D Cohen

Blood Cancer J· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma.
Sundar Jagannath, Thomas G Martin, Yi Lin, Adam D Cohen, Noopur Raje

J Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Belantamab mafodotin does not induce B-cell maturation antigen loss or systemic immune dysfunction in multiple myeloma.
Hanny Musa, Michał Mielnik, Suzanne Trudel, Katja Weisel, Taryn Mockus-Daehn, Adam D Cohen

Haematologica· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Non-tuberculous mycobacterial infections following teclistamab in multiple myeloma.
Matthew Ho, Luca Paruzzo, Janna Minehart, Teja Voruganti, Pooja Devi, Adam D Cohen

Haematologica· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies.
Julie K Jadlowsky, Elizabeth O Hexner, Amy Marshall, Stephan A Grupp, Noelle V Frey, Adam D Cohen, Roger B Cohen

Nat Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma.
Luciano J Costa, Rahul Banerjee, Hira Mian, Katja Weisel, Susan Bal, Adam D Cohen

Leukemia· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma.
Holly Lee, Michael Durante, Sheri Skerget, Deeksha Vishwamitra, Sacha Benaoudia, Adam D Cohen

Blood· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Reasoning: A 49-Year-Old Man With Progressive Numbness, Gait Instability, and Tremors.
Felipe J S Jones, Adam D Cohen, Chafic Karam

Neurology· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paraproteinemic neuropathies.
Rebecca Traub, Taha Qarni, Adam D Cohen, Chafic Karam

Muscle Nerve· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting.
Noopur S Raje, Adam D Cohen, Krina K Patel, Niels W C J van de Donk, Joshua Richter

Clin Lymphoma Myeloma Leuk· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma.
Paula Rodriguez-Otero, Saad Usmani, Adam D Cohen, Niels W C J van de Donk, Xavier Leleu

Lancet Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human IL-6 fosters long-term engraftment of patient-derived disease-driving myeloma cells in immunodeficient mice.
Zainul S Hasanali, Alfred L Garfall, Lisa Burzenski, Leonard D Shultz, Yan Tang, Adam D Cohen

JCI Insight· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma.
Zainul S Hasanali, Beatrice Razzo, Sandra P Susanibar-Adaniya, Alfred L Garfall, Edward A Stadtmauer, Adam D Cohen

Hematol Oncol Clin North Am· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.
Guido Ghilardi, Joseph A Fraietta, James N Gerson, Vivianna M Van Deerlin, Jennifer J D Morrissette, Adam D Cohen

Nat Med· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human IL-6 fosters long-term engraftment of patient derived disease-driving myeloma cells in immunodeficient mice.
Zainul S Hasanali, Alfred L Garfall, Lisa Burzenski, Leonard D Shultz, Yan Tang, Adam D Cohen

bioRxiv· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
Ajay K Nooka, Adam D Cohen, Hans C Lee, Ashraf Badros, Attaya Suvannasankha

Cancer· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Ciltacabtagene Autoleucel in Patients With Prior Allogeneic Stem Cell Transplant in the CARTITUDE-1 Study.
Myo Htut, Binod Dhakal, Adam D Cohen, Thomas Martin, Jesus G Berdeja

Clin Lymphoma Myeloma Leuk· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Options at the time of relapse after anti-BCMA therapy.
Beatrice Razzo, Alfred L Garfall, Adam D Cohen

Hematology Am Soc Hematol Educ Program· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple airway plasmacytomas: A rare cause of proximal airway obstruction requiring tumor debulking.
Christopher Ghiathi, Ashley N Barlev, Gabriel C Caponetti, John P Plastaras, Devraj Basu, Adam D Cohen

Clin Case Rep· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial.
Morie A Gertz, Adam D Cohen, Raymond L Comenzo, Efstathios Kastritis, Heather J Landau

Blood· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Component Costs of CAR-T Therapy in Addition to Treatment Acquisition Costs in Patients with Multiple Myeloma.
Sundar Jagannath, Nedra Joseph, Concetta Crivera, Akshay Kharat, Carolyn C Jackson, Adam D Cohen

Oncol Ther· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plain language summary of the CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma.
Jesus G Berdeja, Adam D Cohen, Thomas Martin, Deepu Madduri, Lida Pacaud

Future Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy.
Alfred L Garfall, Adam D Cohen, Sandra P Susanibar-Adaniya, Wei-Ting Hwang, Dan T Vogl

Blood Cancer Discov· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Progressive multifocal leukoencephalopathy in multiple myeloma.
Brian W Hoeynck, Adam D Cohen, Edward A Stadtmauer, Sandra P Susanibar-Adaniya, Dan T Vogl

Eur J Haematol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis